Acute myeloid leukemia after single-agent treatment with etoposide for Langerhans' cell histiocytosis of bone

Am J Pediatr Hematol Oncol. 1993 May;15(2):255-7. doi: 10.1097/00043426-199305000-00015.

Abstract

The first case of secondary leukemia (FAB M3 microgranular variant) after single-agent chemotherapy with etoposide is described. The peculiar morphology and the absence of previously described cytogenetic abnormalities make this case of interest and emphasize the need for further study of epipodophyllotoxin-related leukemia.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Bone Diseases / complications
  • Bone Diseases / drug therapy*
  • Bone Diseases / genetics
  • Child
  • Etoposide / adverse effects*
  • Female
  • Histiocytosis, Langerhans-Cell / complications
  • Histiocytosis, Langerhans-Cell / drug therapy*
  • Histiocytosis, Langerhans-Cell / genetics
  • Humans
  • Leukemia, Myeloid / chemically induced*
  • Leukemia, Myeloid / genetics
  • Translocation, Genetic

Substances

  • Etoposide